FAM160A2

Across TCGA pan-cancer cohorts, FAM160A2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FAM160A2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM160A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM160A2 expression acts as an unfavorable survival marker.

LUAD, BLCA, and ESCA are the cancer types where FAM160A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.101	0.777	<.001	30	view →
BLCA	OS	Median	All	0.141	0.687	.003	18	view →
ESCA	OS	Median	II,III,IV	0.246	0.706	.001	9	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	All	0.210	0.579	.011	3	view →
SKCM	OS	Median	III,IV	0.649	0.839	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FAM160A2–LUAD (DFS)

Open the LUAD breakdown →